OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).
Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT). OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis. Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
TNF-alpha inhibitors improve nail psoriasis.
Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
OptiSkin Medical
New York, New York, United States
RECRUITINGNAPSI
Nail Psoriasis Severity Index (NAPSI) score is an established measure of nail disease ranging from 0-100. A higher score indicates more severe nails psoriasis.
Time frame: Baseline to 24 weeks
OCT (clinical)
Optical Coherence Tomography is noninvasive imaging that can be used to monitor nail disease severity.
Time frame: Baseline to 24 weeks
OCT (sub-clinical)
Optical Coherence Tomography is noninvasive imaging that will be used to detect subclinical changes in otherwise healthy-appearing nails.
Time frame: Baseline to 24 weeks
Dermoscopy
Dermoscopy allows for the examination of the skin using skin surface microscopy.
Time frame: Baseline to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.